Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
This article was originally published in PharmAsia News
Executive Summary
Partners Amgen and Takeda have pinned near-term oncology growth prospects on motesanib, a vascular endothelial growth factor inhibitor for the treatment of non-small cell lung cancer. Now motesanib is facing a setback; Amgen announced Nov. 19 that the Phase III MONET-1 study has been temporarily suspended after a planned safety review showed earlier mortality rates in the treatment group
You may also be interested in...
Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
Cell therapies have shown promise in treating cancer, but turning their possibility into reality so far has eluded the industry. Therefore, news Oct. 16 that one of the latest-stage therapies in development, Takeda/Cell Genesys' GVAX, failed in a second Phase III clinical trial represents, in some ways, a disappointment for the entire space
AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC
Firm will study VEGF inhibitor plus chemotherapy versus Genentech’s Avastin in first-line colorectal cancer.
Bayer/Onyx’s Nexavar Falters In Lung-Cancer Phase III
Success eludes ESCAPE trial, stopped early by panel finding.